
    
      This open-label, multi center phase II study was conducted to investigate the efficacy and
      safety of the combination of 5-Fluorouracil (5-FU)/folinic acid (FA) plus gemcitabine (GFF)
      in patients (pts) with advanced pancreatic cancer (APC). We consequently started this study
      after completing the phase I trial accomplished by our CONKO- study group.
    
  